OpGen | GenomeWeb

OpGen

The company recently presented preliminary results from two large-scale studies on tracking infections and drug resistance in large hospital systems.

Merck will provide OpGen with access to its library of bacterial pathogens in order to support OpGen's development of rapid DNA tests and a pathogens database.

The company attributed the fall in revenues to decreased sales of rapid pathogen identification and legacy genome mapping products.

The test is based on a biomarker signature that consists of a core set of 31 genes associated with endotoxin tolerance in sepsis patients.

The company said it will use the proceeds for research, development, product manufacturing, and other general corporate purposes.

As LDT developers await an FDA decision on potential new regulations and grapple with reimbursement issues, investors may be unwilling to deal with the uncertainty.   

The company attributed the increase in revenue to a $700,000 increase in product sales, particularly its rapid pathogen ID molecular diagnostic.

Despite the array of tests available, some lab directors are still seeking broader functionalities and capabilities from the systems they purchase.  

While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.